Track Oruka Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Oruka Therapeutics, Inc. ORKA · Stock Open Oruka Therapeutics, Inc. in new tab

85.21 USD
EPS
-1.93
P/B
8.51
ROE
-27.31
Target Price
142.17 USD
Loading chart...
Key Metrics
Earnings dateAug. 10, 2026
EPS-1.93
Book Value9.64
Price to Book8.51
Debt/Equity0.37
% Insiders1.230%
Estimates
Forward P/E-33.34
Forward EPS-2.46
Target Mean Price142.17

DCF Valuation

Tweak assumptions to recompute fair value for Oruka Therapeutics, Inc. (ORKA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Oruka Therapeutics, Inc. Logo Oruka Therapeutics, Inc. Analysis (ORKA)

US Healthcare Official Website Stock

Is Oruka Therapeutics, Inc. a good investment? Oruka Therapeutics, Inc. (ORKA) is currently trading at 85.21 USD. Market analysts have a consensus price target of 142.17 USD. This suggests a potential upside from current levels.

Earnings Schedule: Oruka Therapeutics, Inc. is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is -2.46.

Investor FAQ

Does Oruka Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Oruka Therapeutics, Inc.?

Oruka Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of -1.93.

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Exchange Ticker
NASDAQ ORKA
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
2024
20.97 USD
Aug. 29, 2024 1.6130
Aug. 29, 2024 19.3560
Stock Splits
Split Date Split Ratio to 1
Feb. 23, 2004 0.333333
Jan. 28, 2009 0.050000
March 5, 2013 0.166667
Sept. 4, 2015 0.142857
April 4, 2019 0.055556
Sept. 3, 2024 0.083333
Sept. 3, 2024 0.080000
April 4, 2019 0.060000
Sept. 4, 2015 0.140000
March 5, 2013 0.170000
Feb. 23, 2004 0.330000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion